MBI’s FS069 bid accepted in Europe

Article

Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the

Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the application, MBI and its marketing partner, Mallinckrodt of St. Louis, will be able to sell FS069 in all countries of the European Union.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.